REFERENCES
- Borgers M., Van de Ven M.-A., Van Cutsem J. An ultrastructural study of Aspergillus fumigatus: effects of azoles. Aspergillus and Aspergillosis, H. Vanden Bossche, D.W.R. Mackenzie, G. Cauwenbergh. Plenum Publishing Corp., New York 1988; 199–211, In
- Sanders S.K., Alexander E.L., Braylan R.C. A high-yield technique for preparing cells fixed in suspension for scanning electron microscopy. Journal of Cell Biology 1975; 67: 476–480
- Van Cutsem J., Janssen P.A.J. (1988) Oral and parenteral treatment of invasive aspergillosis in non-predisposed and immunocompromised guinea-pigs with saperconazole (R 66 905) and parenteral treatment with amphotericin B. Abstracts 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, California, October, 1988, 65–65
- Van Cutsem J., Van Gerven F., Janssen P.A.J. The antifungal activity in vitro of saperconazole (R 66 905). Preclinical Research Report on R 66 905 no. 1. Janssen Research Foundation, Beerse December, 1987, 1987
- Van Cutsem J., Van Gerven F., Janssen P.A.J. (1988) R 66 905, a new potent broadspectrum antifungal triazole, oral and parenteral activity. Proceedings Xth Congress of the International Society of Human and Animal Mycology, BarcelonaSpain, June–July, 1–27, Revista Ibérica de Micologia, 5: S1, 02, 11.
- Van Cutsem J., Van Gerven F., Van de Ven M.-A., Borgers M., Janssen P.A.J. Itraconazole, a new triazole that is orally active in aspergillosis. Antimicrobial Agents and Chemotherapy 1984; 26: 527–534
- Vanden Bossche H., Marichal P., Willemsens G., Bellens D., Gorrens J., Roels I., Coene M.-C. R 66 905 a potent and selective inhibitor of the cytochrome P-450-dependent ergosterol synthesis in Candida albicans and Aspergillus fumigatus. Preclinical Research Report on R 66 905 No. 3. Janssen Research Foundation, Beerse 1987